ECM
ADPT icon

ExodusPoint Capital Management’s Adaptive Biotechnologies ADPT Stock Holding History

ExodusPoint Capital Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-15,100
Closed -$734K – 1908
2020
Q3 		$734K Sell
15,100
-8,300
-35% -$349K 0.01% 819
2020
Q2 		$1.13M Buy
+23,400
New +$853K 0.03% 679

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

ExodusPoint Capital Management's ADPT Position: Q1 2026 in Review

ExodusPoint Capital Management opened a new position in Adaptive Biotechnologies (ADPT) in Q1 2026: 555,020 shares worth $7.7M. The stake represents 0.06% of the portfolio and ranks #302 among its holdings. This is a return to the name: ExodusPoint Capital Management previously reported a position in ADPT as recently as Q4 2024.

ExodusPoint Capital Management first reported a position in ADPT in Q2 2019 and has held it in 16 quarters since. 295 funds tracked by Wall St. Rank hold ADPT as of Q1 2026.

  • ExodusPoint Capital Management held 555,020 shares of Adaptive Biotechnologies worth $7.7M as of Q1 2026.
  • Adaptive Biotechnologies was a new ExodusPoint Capital Management position in Q1 2026.
  • Adaptive Biotechnologies made up 0.06% of ExodusPoint Capital Management's portfolio in Q1 2026, its #302 holding.
  • ExodusPoint Capital Management first reported a position in Adaptive Biotechnologies in Q2 2019 and has held it in 16 quarters since.
  • 295 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.